Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment

Gonzales, Rachel; Marinelli‐Casey, Patricia; Shoptaw, Steven; A, Ang; Rawson, Richard A.

doi:10.1016/j.jsat.2006.04.006

Cited by 62 publications

(42 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of cases of MA-related mortality have been reported, not only due to excessive use or overdosing, but also because of hypersensitivity to MA or the drug's prominent hypertensive effects (e.g., Delaney and Estes 1980;Hall et al 1973). In addition, MA abusers have significantly elevated infection rates for diseases such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) as a result of both injection drug use (i.e., needle sharing) and risky sexual behavior (e.g., unprotected sex), especially among the population of men who have sex with men (Bluthenthal et al 2001;Gonzales et al 2006;Halkitis et al 2001;Shoptaw 2006).…”

Section: Effects Of Chronic Methamphetamine Usementioning

confidence: 99%

Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis

et al. 2007

View full text Add to dashboard Cite

This review provides a critical analysis of the central nervous system effects of acute and chronic methamphetamine (MA) use, which is linked to numerous adverse psychosocial, neuropsychiatric, and medical problems. A meta-analysis of the neuropsychological effects of MA abuse/dependence revealed broadly medium effect sizes, showing deficits in episodic memory, executive functions, information processing speed, motor skills, language, and visuoconstructional abilities. The neuropsychological deficits associated with MA abuse/dependence are interpreted with regard to their possible neural mechanisms, most notably MA-associated frontostriatal neurotoxicity. In addition, potential explanatory factors are considered, including demographics (e.g., gender), MA use characteristics (e.g., duration of abstinence), and the influence of common psychiatric (e.g., other substance-related disorders) and neuromedical (e.g., HIV infection) comorbidities. Finally, these findings are discussed with respect to their potential contribution to the clinical management of persons with MA abuse/dependence.

show abstract

Section: Effects Of Chronic Methamphetamine Usementioning

confidence: 99%

Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The immediate somatic effects of MA intake include increased blood pressure and heart rate (Newton et al, 2005), raising the risk for fatal cardiac rhythm disturbances and cerebral hemorrhaging (Mokhlesi et al, 2004) as well as acute coronary syndrome and myocardial infarction (Chen, 2007;Turnipseed et al, 2003;Wijetunga et al, 2004). Moreover, MA using populations are at high risk of infection with Hepatitis C virus (Gonzales et al, 2006) and HIV (Peck et al, 2005;Shoptaw et al, 2003) and frequently develop severe dental decay and multiple caries (Donaldson and Goodchild, 2006). MA users also have significant rates of co-morbid mood and anxiety disorders and are at significantly higher risk of developing a psychotic disorder than the general population and may continue to experience psychotic symptoms even years after stopping MA use (Zweben et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

Shoptaw

Heinzerling

Rotheram-Fuller

et al. 2008

Drug and Alcohol Dependence

Self Cite

138

129

View full text Add to dashboard Cite

Objective-To compare bupropion to placebo for reducing methamphetamine (MA) use, increasing retention, and reducing the severity of depressive symptoms and MA cravings. A secondary objective compared bupropion to placebo for reducing cigarette smoking among MA dependent participants.Methods-Following a 2-week, non-medication baseline screening period, 73 treatment-seeking MA dependent participants were randomly assigned to bupropion sustained release (150 mg twice daily; N=36) or placebo (twice daily; N=37) for 12-weeks under double blind conditions. Participants attended clinic thrice weekly to provide urine samples analyzed for MA-metabolite, to complete research measures and assessments, and to receive contingency management and weekly cognitive behavioral therapy sessions.Results-There were no statistically significant effects for bupropion relative to placebo on MA use verified by urine drug screens, for reducing the severity of depressive symptoms or MA cravings, or on study retention. In a post hoc analysis, there was a statistically significant effect of bupropion treatment on MA use among participants with lighter (0-2 MA-positive urines), but not heavier (3-6 MA-positive urines) MA use during baseline (OR=2.81, 95% CI=1.61-4.93, p<0.001 for MA-free week with bupropion among light users). Bupropion treatment was also associated with significantly reduced cigarette smoking, by almost 5 cigarettes per day (p=0.0002).Conclusion-Bupropion was no more effective than placebo in reducing MA use in planned analyses, though bupropion did reduce cigarette smoking. Post hoc findings of an effect for bupropion among baseline light, but not heavy, MA users suggests further evaluation of bupropion for light MA users is warranted.

show abstract

“…Drug use was a significant risk factor associated with HCV infection 14,[31][32][33][34] , particularly injected drugs 8,15,35 . Use of heroin and speedball were significantly associated with HCV infection, but the risk is much higher among Hispanics than their White-Non Hispanics counterparts.…”

Section: Discussionmentioning

confidence: 99%